446 related articles for article (PubMed ID: 25192602)
1. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
Seghatchian J; Tolksdorf F
Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
4. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
Sandgren P; Diedrich B
Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
[TBL] [Abstract][Full Text] [Related]
5. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
Lozano M; Cid J
Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
[TBL] [Abstract][Full Text] [Related]
6. [Feasibility study for Intercept platelets].
Bardiaux L; Vauzou S; Olivier B; Mathieu-Daude D; Durand E; Dite C; Roubinet F
Transfus Clin Biol; 2016 Nov; 23(4):212-216. PubMed ID: 27644172
[TBL] [Abstract][Full Text] [Related]
7. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro.
Van Aelst B; Feys HB; Devloo R; Vanhoorelbeke K; Vandekerckhove P; Compernolle V
Vox Sang; 2015 May; 108(4):328-39. PubMed ID: 25557250
[TBL] [Abstract][Full Text] [Related]
8. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
[TBL] [Abstract][Full Text] [Related]
9. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
10. Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.
Prudent M; D'Alessandro A; Cazenave JP; Devine DV; Gachet C; Greinacher A; Lion N; Schubert P; Steil L; Thiele T; Tissot JD; Völker U; Zolla L
Transfus Med Rev; 2014 Apr; 28(2):72-83. PubMed ID: 24685438
[TBL] [Abstract][Full Text] [Related]
11. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.
Abonnenc M; Sonego G; Crettaz D; Aliotta A; Prudent M; Tissot JD; Lion N
Transfusion; 2015 Sep; 55(9):2219-30. PubMed ID: 25873361
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen.
Cazenave JP; Aleil B; Wiesel ML; Laforêt M; Isola H
Vox Sang; 2004 Apr; 86(3):201-2. PubMed ID: 15078258
[No Abstract] [Full Text] [Related]
13. LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets.
Prudent M; Sonego G; Abonnenc M; Tissot JD; Lion N
J Am Soc Mass Spectrom; 2014 Apr; 25(4):651-61. PubMed ID: 24470194
[TBL] [Abstract][Full Text] [Related]
14. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
[TBL] [Abstract][Full Text] [Related]
15. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA
Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
[TBL] [Abstract][Full Text] [Related]
16. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.
Cardo LJ; Rentas FJ; Ketchum L; Salata J; Harman R; Melvin W; Weina PJ; Mendez J; Reddy H; Goodrich R
Vox Sang; 2006 Feb; 90(2):85-91. PubMed ID: 16430665
[TBL] [Abstract][Full Text] [Related]
17. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
Cid J
Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
[TBL] [Abstract][Full Text] [Related]
18. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
19. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
Cazenave JP
Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
[TBL] [Abstract][Full Text] [Related]
20. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.
Abonnenc M; Crettaz D; Sonego G; Escolar G; Tissot JD; Prudent M
Transfus Clin Biol; 2019 Nov; 26(4):209-216. PubMed ID: 31563447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
